Centessa Pharmaceuticals PLC ADR (CNTA) - Total Assets
Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) holds total assets worth $687.50 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Centessa Pharmaceuticals PLC ADR's book value for net asset value and shareholders' equity analysis.
Centessa Pharmaceuticals PLC ADR - Total Assets Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's total assets have evolved over time, based on quarterly financial data.
Centessa Pharmaceuticals PLC ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
Centessa Pharmaceuticals PLC ADR's total assets of $687.50 Million consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Centessa Pharmaceuticals PLC ADR (CNTA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Centessa Pharmaceuticals PLC ADR's current assets represent 53.5% of total assets in 2025, a decrease from 97.5% in 2019.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2025, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Centessa Pharmaceuticals PLC ADR Competitors by Total Assets
Key competitors of Centessa Pharmaceuticals PLC ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Centessa Pharmaceuticals PLC ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.57 | 9.25 | 16.53 |
| Quick Ratio | 8.57 | 9.25 | 16.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $324.94 Million | $478.41 Million | $294.66 Million |
Centessa Pharmaceuticals PLC ADR - Advanced Valuation Insights
This section examines the relationship between Centessa Pharmaceuticals PLC ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.65 |
| Latest Market Cap to Assets Ratio | 8.87 |
| Asset Growth Rate (YoY) | 19.2% |
| Total Assets | $687.50 Million |
| Market Capitalization | $6.10 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Centessa Pharmaceuticals PLC ADR's assets at a significant premium (8.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Centessa Pharmaceuticals PLC ADR's assets grew by 19.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual total assets of Centessa Pharmaceuticals PLC ADR from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $687.50 Million | +19.19% |
| 2024-12-31 | $576.80 Million | +60.11% |
| 2023-12-31 | $360.25 Million | -18.92% |
| 2022-12-31 | $444.31 Million | -29.43% |
| 2021-12-31 | $629.63 Million | +5273.69% |
| 2020-12-31 | $11.72 Million | -40.61% |
| 2019-12-31 | $19.73 Million | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more